Lexicon Pharmaceuticals (LXRX) Short Interest Ratio & Short Volume

Lexicon Pharmaceuticals logo
$1.75 -0.04 (-2.23%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.75 0.00 (0.00%)
As of 11/16/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexicon Pharmaceuticals Short Interest Overview

As of October 30, 2026, Lexicon Pharmaceuticals (LXRX) had a short interest of 25.88 million shares sold short, representing 6.76% of the public float. This marks a 3.09% decrease in short interest since the prior report. The short interest ratio (days to cover) is 14.0, meaning it would take 14.0 days of the average trading volume of 2.18 million shares to cover all short positions.

Current Short Interest
25,877,882 shares
Previous Short Interest
26,703,932 shares
Change Vs. Previous Report
-3.09%
Dollar Volume Sold Short
$36.75 million
Short Interest Ratio
14.0 Days to Cover
Last Record Date
October 30, 2026
Outstanding Shares
445,230,000 shares
Short Percent of Float
6.76%
Today's Trading Volume
1,481,909 shares
Average Trading Volume
2,179,859 shares
Today's Volume Vs. Average
68%
Short Selling Lexicon Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History

LXRX Short Interest Over Time

LXRX Days to Cover Over Time

LXRX Percentage of Float Shorted Over Time

Lexicon Pharmaceuticals Tesla Short Interest History & Recent Changes

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/30/202625,877,882 shares $36.75 million -3.1%6.8%14.04 $1.42
10/15/202626,703,932 shares $44.06 million +3.4%7.0%12.97 $1.65
9/30/202625,828,112 shares $48.43 million -10.3%6.7%6.16 $1.88
9/15/202628,793,507 shares $57.87 million -2.4%7.5%13.4 $2.01
8/31/202629,490,809 shares $66.35 million -10.0%7.7%10.28 $2.25
8/14/202632,749,669 shares $75.98 million -0.2%8.6%10.93 $2.32
7/31/202632,825,365 shares $75.83 million +0.3%8.6%12.46 $2.31
7/15/202632,730,919 shares $72.01 million +6.3%8.6%12.03 $2.20
6/30/202630,784,601 shares $73.88 million +21.1%8.1%4.44 $2.40
6/15/202625,425,636 shares $49.83 million -3.0%6.7%12.62 $1.96
5/29/202626,206,147 shares $57.13 million +0.3%6.9%13.74 $2.18
5/15/202626,140,915 shares $58.29 million +9.6%6.8%6.22 $2.23
4/30/202623,857,393 shares $38.41 million +0.8%6.2%13.59 $1.61
4/15/202623,674,019 shares $44.03 million +3.2%6.2%11.62 $1.86
3/31/202622,932,295 shares $35.77 million +1.1%6.0%9.07 $1.56
3/13/202622,693,812 shares $38.35 million -1.9%6.2%7.14 $1.69
2/27/202623,139,559 shares $34.02 million -5.6%6.3%12.65 $1.47
2/13/202624,523,367 shares $32.13 million -0.3%6.4%8.57 $1.31
1/30/202624,583,755 shares $28.52 million -2.3%7.9%4.69 $1.16
1/15/202625,160,782 shares $32.21 million +6.3%8.0%17.95 $1.28
12/31/202523,660,410 shares $27.21 million +1.4%7.6%12.34 $1.15
12/15/202523,344,944 shares $28.71 million -3.6%7.5%16.82 $1.23
11/28/202524,226,907 shares $34.16 million -1.7%7.7%16.97 $1.41
11/14/202524,649,659 shares $36.73 million -11.0%7.9%8.42 $1.49
10/31/202527,704,594 shares $38.23 million +3.2%8.9%16.5 $1.38
10/15/202526,830,000 shares $41.05 million -1.7%8.6%11.2 $1.53
9/30/202527,300,000 shares $36.86 million -3.8%N/A10.1 $1.35
9/15/202528,380,000 shares $31.79 million -1.6%N/A8.8 $1.12
8/31/202528,840,000 shares $31.72 million +3.3%9.2%8.6 $1.10
8/15/202527,910,000 shares $34.61 million +3.1%N/A7.6 $1.24
7/31/202527,060,000 shares $28.95 million -7.4%8.6%6.6 $1.07
7/15/202529,210,000 shares $33.59 million -12.0%N/A6.2 $1.15
6/30/202533,210,000 shares $31.41 million -11.6%10.7%6.1 $0.95
6/15/202537,560,000 shares $25.22 million -3.3%12.1%2.8 $0.67
5/31/202538,830,000 shares $24.94 million -9.8%16.9%2.9 $0.64
5/15/202543,030,000 shares $22.81 million +15.5%18.8%2.9 $0.53
4/30/202537,270,000 shares $27.24 million -9.8%N/A2.5 $0.73
4/15/202541,330,000 shares $21.17 million -5.8%18.0%2.8 $0.51
3/31/202543,880,000 shares $20.22 million +11.8%19.1%3 $0.46
3/15/202539,260,000 shares $14.39 million -17.3%17.1%6.3 $0.37
Pentagon magnet restrictions take effect January 1, 2027 (Ad)

A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel

Read the full breakdown of the proposed Army rare earth agreement and the company behind it.
2/28/202547,460,000 shares $33.51 million +6.1%20.7%7.3 $0.71
2/15/202544,740,000 shares $35.12 million +4.0%19.5%9.3 $0.78
1/31/202543,030,000 shares $32.54 million +10.1%N/A9 $0.76
1/15/202539,100,000 shares $28.45 million +16.7%N/A8 $0.73
12/31/202433,500,000 shares $24.74 million +7.1%N/A7.8 $0.74
12/15/202431,280,000 shares $25.35 million -0.8%N/A7.6 $0.81
11/30/202431,530,000 shares $25.22 million +0.5%N/A9.6 $0.80
11/15/202431,380,000 shares $30.60 million +9.5%N/A9.7 $0.98
10/31/202428,650,000 shares $55.87 million +3.6%N/A9.5 $1.95
10/15/202427,650,000 shares $49.49 million +2.5%N/A10.1 $1.79
9/30/202426,970,000 shares $42.34 million +1.3%N/A9.4 $1.57
9/15/202426,630,000 shares $45.27 million +4.9%N/A9.5 $1.70
8/31/202425,390,000 shares $43.92 million +3.5%N/A8.8 $1.73
8/15/202424,530,000 shares $40.23 million +9.8%N/A8.5 $1.64
7/31/202422,350,000 shares $50.29 million +7.0%N/A8 $2.25
7/15/202420,880,000 shares $44.27 million +3.4%N/A7.6 $2.12
6/30/202420,200,000 shares $33.94 million -6.4%N/A7.8 $1.68
6/15/202421,570,000 shares $39.26 million -14.2%N/A7.7 $1.82
5/31/202425,140,000 shares $42.74 million +8.0%N/A7.3 $1.70
5/15/202423,270,000 shares $45.14 million -0.7%N/A6.3 $1.94
4/30/202423,440,000 shares $36.10 million +16.5%N/A5.3 $1.54
4/15/202420,120,000 shares $37.62 million -8.2%N/A4.2 $1.87
3/31/202421,910,000 shares $52.58 million +2.6%N/A4.7 $2.40
3/15/202421,350,000 shares $55.51 million +1.3%N/A4.6 $2.60
2/29/202421,070,000 shares $52.46 million -10.0%N/A4.9 $2.49
2/15/202423,410,000 shares $83.81 million +1.7%N/A6.4 $3.58
1/31/202423,030,000 shares $43.07 million -8.9%N/A8 $1.87
1/15/202425,270,000 shares $34.62 million +8.8%N/A10.3 $1.37
12/31/202323,220,000 shares $35.53 million -0.3%N/A8.6 $1.53
12/15/202323,280,000 shares $29.57 million -0.5%N/A9.1 $1.27
11/30/202323,400,000 shares $24.80 million +4.6%N/A9.3 $1.06
11/15/202322,370,000 shares $25.50 million +1.8%N/A9.3 $1.14
10/31/202321,980,000 shares $27.26 million +12.7%N/A9.9 $1.24
10/15/202319,500,000 shares $23.21 million -3.7%N/A9.1 $1.19
9/30/202320,240,000 shares $22.06 million +7.1%N/A11.2 $1.09
9/15/202318,900,000 shares $26.46 million +6.1%N/A11.5 $1.40
8/31/202317,810,000 shares $30.63 million +1.5%N/A9.5 $1.72
8/15/202317,550,000 shares $28.61 million -2.2%N/A6.6 $1.63
7/31/202317,950,000 shares $36.08 million +14.2%N/A6.9 $2.01
7/15/202315,720,000 shares $34.74 million +8.7%N/A6.3 $2.21
6/30/202314,460,000 shares $33.11 million +38.0%N/A6.1 $2.29
6/15/202310,480,000 shares $26.93 million -2.6%N/A4.9 $2.57
5/31/202310,760,000 shares $35.51 million +66.8%N/A6.3 $3.30
5/15/20236,450,000 shares $19.22 million +30.8%N/A8.5 $2.98
4/30/20234,930,000 shares $11.78 million +17.4%N/A8.1 $2.39
4/15/20234,200,000 shares $10.12 million +3.5%N/A9.5 $2.41
3/31/20234,060,000 shares $9.87 million +2.3%N/A10.3 $2.43
3/15/20233,970,000 shares $9.09 million +4.2%N/A9.3 $2.29
2/28/20233,810,000 shares $8.57 million -8.0%N/A9.3 $2.25
2/15/20234,140,000 shares $9.44 million +3.5%N/A11.3 $2.28
Buy Stocks… A Crash is Coming (Ad)

Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel

See Jim Rickards' 2027 prediction before the November 30th deadline arrives.
1/31/20234,000,000 shares $8.96 million +2.6%N/A10.6 $2.24
1/15/20233,900,000 shares $9.20 million +0.3%N/A9.8 $2.36
12/30/20223,890,000 shares $7.43 million +2.9%N/A9.3 $1.91
12/15/20223,780,000 shares $8.05 million +0.3%N/A8.6 $2.13
11/30/20223,770,000 shares $8.07 million -2.3%N/A7.8 $2.14
11/15/20223,860,000 shares $8.96 million -9.4%N/A7.5 $2.32
10/31/20224,260,000 shares $9.16 million -4.7%N/A6.4 $2.15
10/15/20224,470,000 shares $9.43 million -0.2%N/A4.4 $2.11
9/30/20224,480,000 shares $10.75 million +11.4%N/A4.3 $2.40
9/15/20224,020,000 shares $10.77 million +7.8%N/A2.4 $2.68
8/31/20223,730,000 shares $10.26 million +1.9%N/A2.2 $2.75
8/15/20223,660,000 shares $12.55 million -55.2%N/A2.2 $3.43
7/31/20228,170,000 shares $19.44 million -0.9%N/A5.3 $2.38
7/15/20228,240,000 shares $25.38 million +6.6%8.0%6.9 $3.08
6/30/20227,730,000 shares $14.38 million +34.4%7.5%6.6 $1.86
6/15/20225,750,000 shares $8.05 million +5.7%5.6%10.5 $1.40
5/31/20225,440,000 shares $9.63 million +1.3%N/A10.9 $1.77
5/15/20225,370,000 shares $9.29 million +0.9%N/A8.8 $1.73
4/30/20225,320,000 shares $9.63 million +11.5%N/A8.4 $1.81
4/15/20224,770,000 shares $11.11 million +2.8%N/A7.3 $2.33
3/31/20224,640,000 shares $9.70 million -2.1%N/A7.1 $2.09
3/15/20224,740,000 shares $9.24 million -2.1%N/A6.8 $1.95
2/28/20224,840,000 shares $10.02 million +8.3%N/A6.8 $2.07
2/15/20224,470,000 shares $13.50 million +17.6%N/A7 $3.02
1/31/20223,800,000 shares $12.05 million +5.3%N/A5.9 $3.17
1/15/20223,610,000 shares $12.45 million +1.4%N/A5.6 $3.45
12/31/20213,560,000 shares $14.03 million +10.9%N/A5 $3.94
12/15/20213,210,000 shares $12.78 million -10.6%N/A4.3 $3.98
11/30/20213,590,000 shares $16.44 million -0.6%N/A4.9 $4.58

LXRX Short Interest - Frequently Asked Questions

Short interest is the volume of Lexicon Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 30th, traders have sold 25,877,882 shares of LXRX short. 6.76% of Lexicon Pharmaceuticals' shares are currently sold short. Learn More on Lexicon Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LXRX shares currently have a short interest ratio of 14.0. Learn More on Lexicon Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.76% of Lexicon Pharmaceuticals' floating shares are currently sold short.

Lexicon Pharmaceuticals saw a decrease in short interest since the prior report. As of October 30th, there was short interest totaling 25,877,882 shares, a decrease of 3.1% from the previous total of 26,703,932 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

6.76% of Lexicon Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Lexicon Pharmaceuticals: Xencor, Inc. (18.11%), Zai Lab Limited Unsponsored ADR (6.80%), NewAmsterdam Pharma Company N.V. (11.51%), Arcus Biosciences, Inc. (9.90%), Celldex Therapeutics, Inc. (13.34%), ADMA Biologics Inc (8.38%), Palvella Therapeutics, Inc. (21.81%), Vericel Corporation (11.34%), Vera Therapeutics, Inc. (20.03%), Biohaven Ltd. (11.53%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($77.66 billion), Invesco QQQ ($57.17 billion), iShares Russell 2000 ETF ($21.91 billion), SPDR S&P Biotech ETF ($10.53 billion), Union Pacific Corporation ($9.26 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($9.05 billion), Nebius Group N.V. ($7.85 billion), iShares 20+ Year Treasury Bond ETF ($7.81 billion), Moderna, Inc. ($7.36 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.20 billion). View all of the most shorted stocks.

Short selling LXRX is an investing strategy that aims to generate trading profit from Lexicon Pharmaceuticals as its price is falling. LXRX shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lexicon Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LXRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LXRX, twice per month. The most recent reporting period available is October, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like LXRX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.



Short interest data for NASDAQ:LXRX is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 11/10/2026. FINRA publishes updated short interest twice a month.
From Our Partners